Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variet... Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. 詳細を表示
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.51 | 11.7601246106 | 12.84 | 14.6935 | 12.5106 | 31426 | 13.50160186 | CS |
4 | 0.1 | 0.701754385965 | 14.25 | 14.79 | 11.89 | 30507 | 13.5105854 | CS |
12 | 1.09 | 8.22021116139 | 13.26 | 16.5 | 11.89 | 31015 | 13.98611295 | CS |
26 | 0.43 | 3.08908045977 | 13.92 | 18.7499 | 11.89 | 37659 | 15.10163653 | CS |
52 | 2.35 | 19.5833333333 | 12 | 21.44 | 8 | 37235 | 14.35233143 | CS |
156 | -19.6 | -57.7319587629 | 33.95 | 36.2726 | 6.8241 | 63492 | 13.14936785 | CS |
260 | 9.35 | 187 | 5 | 158.07 | 3.262 | 145007 | 36.18518614 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約